Sun Pharma, Taro Get Final Approval of $200 Million Antitrust Deal

Sun Pharmaceutical Industries Inc. and its subsidiary Taro Pharmaceuticals USA Inc. gained final approval of a $200 million antitrust deal to settle claims they conspired with other drugmakers to inflate generic drug prices.

Judge Cynthia M. Rufe of the US District Court for the Eastern District of Pennsylvania in a Jan. 23 order said the settlement with end-payer plaintiffs included sufficient discovery and that various factors, including expense and likely duration of the litigation, weighed in favor of approval.

Sun’s effort adds to other settlements in the case, including Sandoz Inc.'s deal for $275 million.

The litigation dates to ...